Molecular Devices will distribute ChanTest’s portfolio of ion channel and GPCR cell lines on a nonexclusive basis. In addition, ChanTest's cell-optimization services will be promoted by Molecular Devices to its PatchXpress® 7000A, IonWorks® Quattro, IonWorks Barracuda™, and FLIPR® Tetra system customers worldwide.
ChanTest has a portfolio of more than 145 ion channel and 110 GPCR cell lines.
“Providing more high-quality options to a larger group of customers naturally will bring more visibility to our best-in-class ion channel cell lines and complement them perfectly,” says ChanTest’s founder, Arthur M. Brown, M.D., Ph.D.
Founded in 1998, ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents. The company has tested compounds for more than 500 global pharmaceutical and biotechnology companies, with which it partners with the goal of speeding up drug development.
Molecular Devices is a unit of Danaher, which last month announced plans to acquire Beckman Coulter for $6.8 billion.